Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
The ESC is proud to launch its second edition of the Professional Horizons at ESC Congress 2018 in Munich!
In a relaxed atmosphere, in the Professional Members’ Lounge, meet Internationally renowned experts in your field.
The ESC Professional Horizons is the meeting place for the future generation of cardiologists to interact with the great leaders of their specialty.
During individual interviews of 20 minutes, the selected applicants have the privilege to seek career development advice and recommendations from renowned professionals with years of successful careers behind them.
This is a unique platform where long-lasting generational relationships are possible!
Professional Horizons will take place on:
Applicants have to be:
IMPORTANT: Applicants must be sure not to have any conflicting role at the same time.
To apply, please follow the below instructions:
Deadline to apply: Monday 13th August
Deadline to apply: Monday 13th August
Results will be given mid-August.
Sunday 26 August
15:30 to 16:30
Monday 27 August
Tuesday 28 August
Marisa CRESPO LEIRO
Rudolf De BOER
Marco De CARLO
Carol Ann REMME
Theme Heart and Vessels, Division of Valvular and Coronary Disease, Karolinska University Hospital, S2:02; 171 76 Stockholm, Sweden. Magnus.Back@ki.se / Twitter: @TransCardio
After receiving his MD in 1998 and PhD in 2001, Magnus Bäck is presently Professor of Cardiology at the Karolinska University Hospital and Group Leader for Translational Cardiology at the Center for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden. His present research is focused on translational studies of inflammation in cardiovascular disease, in particular lipid mediators, atherosclerosis and valvular heart disease.
Magnus Bäck’s area of expertise is translational cardiovascular research and the combination of clinical cardiology with experimental research.
Emanuele Barbato, MD, PhDInterventional Cardiologist Associate Professor of CardiologyDepartment of Advanced Biomedical SciencesUniversity of Naples Federico II, Italy
In 1997, he graduated in Medicine, and in 2001 he obtained the board certification in Cardiology at the University of Naples Federico II. During the medical school he attended in the frame of a short-stay research fellowship, sponsored by the University of Naples Federico II, the Cardiology Molecular Lab of prof. Walter J. Koch at the Duke University in North Carolina. From Jan 2001 to Dec 2002, he was Clinical Research Fellow at the Cardiovascular Research Center of Aalst (Belgium). In May 2006, he completed the PhD in Cardiovascular Pathophysiology at the University Tor Vergata in Rome. In 2007, Prof. Barbato was appointed as Associate Director of the Cardiovascular Research Center Aalst (Belgium) and as of 2008 he was appointed as Director of the related Clinical Research Unit. In 2013, he has been visiting professor at the II Faculty of Medicine of the University of Rome La Sapienza. In 2013, he obtained the Italian scientific certification of Associate Professor of Cardiology. In 2014, he has been appointed as Associate Professor of Cardiology at the Department of Advanced Biomedical Sciences of the University of Naples Federico II. In 2017, he obtained the Italian scientific certification as Full Professor of Cardiology.
Prof. Barbato has been author of more than 170 peer-reviewed articles (see PubMed) in the field of pathophysiology of the coronary flow, of the ischemic cardiomyopathy, interventional cardiology, and platelet pathophysiology. He has been member of several Scientific and Learned Societies, and member of Editorial Boards of scientific journals (European Heart Journal, Journal Cardiovascular Translational Research, Journal Cardiovascular Medicine). He has served as member of the Programme Committee of the EuroPCR and of the EAPCI. As of 2014, he has chaired the National Cardiac Societies and International Affairs Committee of the EAPCI. As of 2018, he serves as EAPCI secretary. He has been recipient of National and International research awards (Scholar in Cardiology and William Harvey prize of the Italian Society of Cardiology, and Parmley prize of the American College of Cardiology).
Area of expertise: PCI, TAVI, STEMI treatment, Stents, clinical trials
Andreas Baumbach is Professor of Cardiology and Consultant Interventional Cardiologist at the Barts Heart Centre and Queen Mary University London. Prior to his appointment in London, he was honorary Professor of Interventional Cardiology at the University of Bristol.He has published extensively in the field of interventional research covering preclinical research, first in man, pivotal and post market studies. Professor Baumbach has a strong commitment to training and education. He is on the board of directors of the largest interventional congress EuroPCR. He is the President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
Marie-Luce Bochaton-Piallat completed her PhD in Biochemistry at the Faculty of Medicine of the University of Geneva in 1993. During her post-doctoral studies she was scientific coordinator at the Bioimaging Core Facility at the Faculty of Medicine until 2002 when she became an independent research group leader. She teaches cardiovascular pathophysiology at the Faculty of Medicine. She is a fellow of the ESC, ex-officio member and incoming vice-chair of the Working Group Atherosclerosis and Vascular Biology of the ESC. She also serves as member of the scientific committee of the Swiss CardioVascular Biology Working Group and section editor of The European Society of Cardiology Textbook of Vascular Biology. Recently she co-edited a spotlight issue on Novel concept for the role of smooth muscle cells in vascular disease in CardioVascular Research.
She has a longstanding experience in the implication of smooth muscle cell heterogeneity in atherosclerosis and restenosis. She is working with the porcine coronary artery smooth muscle cells. Thanks to this experimental model, she identified the S100A4, a calcium-binding protein, as a marker of intimal smooth muscle cells, in both pig and human. She is currently investigating the role of S100A4 in the phenotypic modulation of intimal smooth muscle cells in vitro and in vivo. Since 2002 she receives continuous support from the Swiss National Science Foundation for her research. Her h-index is 32.
Nikolas Bonaros is a senior consultant at Innsbruck University Hospital and an Associate Professor of Cardiac Surgery at the Medical University of Innsbruck.
His main interests are totally endoscopic and minimally invasive coronary and valve procedures including robotics and 3D visualization. He is director of an interdisciplinary program for transcatheter aortic and mitral valve interventions in Innsbruck. He has participated in several multicenter trials on coronary surgery, hybrid coronary revascularization and sutureless and transcatheter valve interventions. His experimental interests focus on stem cell therapy and myocardial regeneration as well as on imaging techniques to facilitate minimally invasive procedures.
Area of expertise: First scientific focus were vasculitis disorders and experimental approach to different vascular biomarkers, than followed by imaging of peripheral vessels. Recent main focus of scientific and daily work is the area of endovascular therapy in peripheral vessels, as well as modern antithrombotic treatment of PAD.
After attending Medical School in Graz Austria, training in Internal Medicine at the University Hospital Graz. Special training in Vascular Medicine/Angiology and since 2004 Professor for Internal Medicine and Angiology. Since 2015 Substitute Head of Division of Angiology/Vascular Medicine at the University Hospital Graz, Austria.
Past activities included chairs/presidency of local and international societies/working groups in the vascular field (Austrian Vascular Society, ESVM, ESC WG Peripheral Field) and involvement in strategic decisions in the peripheral vascular field.
Area of expertise:
Nico Bruining started his career in 1985, after completing his technical computer sciences studies, as a cathlab technician working with Professor's P.W. Serruys and de Feyter at the Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands. In 1993 he joined the department of Clinical and Experimental Information processing at the Thoraxcenter as a researcher with as focus cardiovascular imaging, currently is the head of the department. He was involved in the early developments of three-dimensional (3-D) echocardiography, culminating in 1998 with the defense of his PhD thesis - “Quantitative 3-D Echocardiography of the Heart and the Coronary Vessels” under the promotorship of Prof. J.R.T.C Roelandt.
Area of expertise: Non invasive cardiovascular imaging and, in particular, cardiac MRI.
Chiara Bucciarelli-Ducci is a consultant senior lecturer in cardiology/non invasive imaging at the University of Bristol, United Kingdom. She is also the co-director of the Clinical Research & Imaging Centre (CRIC) Bristol. She is one of the vice-Presidents of European Association of Cardiovascular Imaging (EACVI) of the ESC and the current chair of the cardiovascular MRI section.
She was one of awardees of the ESC grants to attend the Oxford Women Transforming Leadership course in 2015.
Area of expertise: Senior Interventional Cardiologist and Director of Research in Interventional Cardiology Unit, San Raffaele Hospital (Director Dr A. Colombo), Milan, Italy.
Scientific Coordinator and Adjunct Professor of the Master in Interventional Cardiology at University Vita e Salute del Monte Tabor –Milan, Italy.
Adjunct Professor in “Scuola in Malattie dell’Apparato Cardiovascolare” at University Vita e salute del Monte Tabor.
Over 300 peer reviewed original articles on several topics including preliminary experience with drug-eluting stent implantation intraprocedural stent thrombosis; drug-eluting stent implantation in unprotected left main coronary artery lesions; drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis; histopathology of clinical coronary restenosis in drug- eluting versus bare metal stents, bioabsorbable scaffolds, optimal duration of dual antiplatelet therapy after PCI, radiation protection for healthcare providers, transcatheter aortic valve implantation, gender disparities in cardiovascular disease, Co-Investigator and global or country or local PI of Major Sponsored International Multicentre Clinical Trials and Spontaneous Single and Multi Center International Clinical Studies.
Area of expertise: Her main fields of research interest are heart failure and heart transplantation.
Coordinator of the Advanced & Specialized Heart Failure (HF) and Heart Transplant (HT) Unit at the Complexo Hospitalario Universitario A Coruña (CHUAC), Spain and Associate Professor of Medicine. She obtained MD at the University of Santiago de Compostela, Specialization in cardiology at Clinica Puerta de Hierro in Madrid and PhD from Universidad Autónoma de Madrid.
Rudolf de Boer (1972, Gouda, the Netherlands) is a Clinical Cardiologist and a Full Professor of (Translational) Cardiology at the University Medical Center Groningen, the Netherlands. He studied medicine at the University of Groningen and, previous to his current appointment, completed a research fellowship at the University of Utah, Salt Lake City, USA, a PhD program at the University of Groningen, and a post-doctoral fellowship at Harvard Medical School, Boston, USA. He heads a research group conducting translational research projects, and has published over 250 articles. He was appointed a Fellow of the European Society of Cardiology (ESC), is president of the Heart Failure Working Group of the Dutch Society of Cardiology, Board Member of the Heart Failure Association (HFA) of the ESC, coordinator of the HFA committee on Heart Failure with Preserved Ejection Fraction (HFpEF), and co-coordinator of the study group on Biomarkers.
His research group focuses on novel genes involved in cardiac remodeling, fibrosis, metabolic changes, and diabetes, always trying to connect clinical observations to preclinical and mechanistic studies. The last 5 years, he has studied galectin-3 in clinical heart failure and in the general population, and focused on its role in the pathophysiology of heart failure. Recently he focuses on interaction of heart failure and co-morbidities, including cancer. He was a founding member the scientific committee of LifeLines, a population study of 165,000 subjects of the Northern part of the Netherlands. Doctor de Boer’s clinical interests are cardiogenetics, echocardiography and end-stage heart failure including VAD therapy and transplant.
1. interventional treatment of acute coronary syndrome2. coronary physiology3. endovascular treatment of carotid stenosis4. endovascular treatment of peripheral artery disease 5. TAVI6. transcatheter mitral interventions
I am Vice-Director of the Cardiac Catheterization Laboratory and Professor at the School of Specialization in Cardiology of Pisa University. I am active in clinical research, in particular in the field of interventional treatment of coronary artery disease, carotid and peripheral artery disease, and valvular heart disease. I am the Chairman of the Working Group on Aorta and Peripheral Vascular Diseases of the European Society of Cardiology. I authored 135 peer-reviewed papers.
Area of expertise: Hypertension, ACS, Heart Failure
Area of expertise: Poly-vascular atherosclerosis, peripheral arterial disease, inflammation
My research career commenced in Cambridge where I studied the immunology of transplant rejection as a PhD in Professor Graeme Alexander’s lab. Following Post-doctoral positions at the Fred Hutchinson Cancer Research Center (Seattle, USA) and the Babraham Institute, Cambridge, UK (with Dr Peter Kilshaw), I was awarded Training and Senior Fellowships by Kidney Research UK to study the intracellular signalling pathways that control activation and injury of endothelial cells. This led to my discovery of a family of deubiquitinating enzymes that suppress inflammation by inhibiting the transcription factor NF-kB. Its significance was recognized by the British Transplantation Society who awarded me the Medawar Prize in 2000. I joined Imperial College London in 2004 as a Senior Lecturer (Reader in 2010) and established the Intracellular Signalling Laboratory within the BHF Cardiovascular Sciences Unit (headed by Prof. Dorian Haskard). I was appointed Chair of Cardiovascular Science at the University of Sheffield in 2011.
Research Interests: My research focuses on the biomechanical mechanisms that control atherosclerosis, a disease of arteries that can lead to angina, heart attack and stroke. Branches and bends of arteries are prone to atherosclerosis because complex patterns of blood flow at these sites generate frictional forces (shear stress) that trigger pathophysiological changes in endothelial cells. My laboratory combines genomics approaches with unbiased functional screening and biochemical studies to identify the signaling pathways and transcriptional programs that regulate endothelial cell responses to flow. The goal is to identify molecules within these pathways that can be targeted to prevent or treat atherosclerosis. The cross-disciplinary nature of my work has led to interactions with physicist and engineers as well as molecular and cellular biologists and clinical scientists.
I have received >£5.8M research funding as Principal Investigator (PI) including a £1M BHF Program awarded in 2013. My research has been recognized by the British Atherosclerosis Society (John French Lecture) and the British Cardiovascular Society (Michael Davies Award). I have trained 20 PhD/MD students to completion (13 as 1st supervisor), 14 MSc/MRes students and mentored 12 Post-doctoral Research Associates, of whom three have subsequently obtained PI positions in other universities. Members of my laboratory have won 17 prestigious national or international prizes including the European Society for Cardiology Young Investigator First Prize and UK Young Life Scientist First Prize.
Area of expertise: infarction, heart failure, cardioprotection, their interaction with co-morbidities and co-medication, transcriptomics, translational studies, clinical pharmacology
Péter Ferdinandy is a professor of pharmacology and clinical pharmacology, director of the Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest (www.semmelweis.hu/pharmacology). He received an MD diploma in 1991 and a PhD degree in 1995 from the University of Szeged, Szeged, Hungary. He became a registered clinical pharmacologist in 1999, and obtained a DSc degree of the Hungarian Academy of Sciences in 2004. He completed MBA studies in Finance and Quality Management in 2004 at the Budapest University of Technology and Economics.
He was a postdoctoral fellow of MRC Canada for 2 years at the Department of Pharmacology, University of Alberta, Edmonton, Canada. He was the head of the Cardiovascular Projects at Biorex Co (a partner of Abbott) for 2 years, a US-Hungarian biotech company, and consulted hundreds of preclinical and clinical pharmacological projects for several pharmaceutical companies all over the world in the last 20 years. He is the founder and CEO of Pharmahungary Group, a group of R&D companies (www.pharmahungary.com).
He published over 200 papers in international peer-reviewed journals and he is listed among the most influential scientists in the field of pharmacology on Highlycited 2014 and 2017 (www.highlycited.com). He is member of the editorial boards of Br J Pharmacol, Basic Res Cardiol, J Mol Cell Cardiol, and J Pharmacol Toxicol Methods. He was the president of the International Society for Heart Research, European Section, and currently the past chair of the Working Group of Cellular Biology of the Heart, European Society of Cardiology.
He graduated from Paris university in 1983 and received his doctor of Medicine in 1984. He then underwent a general surgery training at St Vincents hospital in New York from 1984 to 1989, then in cardiothoracic surgery in SUNY health in Brooklyn from 1989 to 1992. Successfully passed the American Board of Surgey and American Board of CardioThoracic Surgery, and became Fellow of the American College of Surgery in 1996.. After completion of his US training he did a two year fellowship in Marie Lannelongue in adult and pediatric surgery. Became staff surgeon at Institut Mutualiste Montsouris in 1994, he started a mini invasive program with robotic in 2004 for CABG and mitral valve repair.
He then became full Professor of CardioThoracic surgery in 2012 and head of the department of cardiovascular and transplantation of the University of Lorraine in Nancy. His main interest is in the field of minimally invasive valvular cardiac surgery. He the author or coauthor of more than 200 publications.
He is currently the chairman of the Cardiovascular group of the nucleus of the European Society of Cardiology, and the President of the European Society of Endovascular Surgery.
Marco Guazzi, MD, PhD, FESC, FACC, FAHA. Professor of Cardiology at the University of Milano and Head of the University Department of Cardiology at IRCCS San Donato University Hospital, Milano.
He is the author or co-author of over 500 manuscripts. He is appointed to the Board of the European Association of Cardiovascular Prevention (EACP) and Rehabilitation of the European Society of Cardiology. He serves on the Editorial Board of the Journal of Cardiac Failure, and is Associate Editor of the European Journal of Prevention.
Area of expertise: Interventional cardiology including coronary, structural and valvular catheter-based interventions, intracoronary imaging and pressure-wire applications
Area of expertise: Interventional cardiology, clinical research, antithrombotic treatment, acute coronary syndromes, mechanical support in cardiogenic shock and cardiac arrest
I am an interventional cardiologist at Rigshospitalet, Copenhagen, where I have been employed since I finished my specialist training in 2007.
My main clinical interests are primary PCI as well as mechanical support in cardiogenic shock and after cardiac arrest and I am a full-time member of our 24/7 on-call PCI team. I have been involved in research since I was in medical school, and although it’s not my main job, I enjoy being supervisor for my PhD students.
I have always had an interest in shaping how we are treating patients in Denmark. In our country we have a fully tax-based health system, and I believe it is very important, that clinicians are involved in setting standards for treatment by influencing authorities such as the Danish Board of Health.
Area of expertise: heart failure, pharmacology, stem cells, biotherapies
Dr Jean-Sébastien Hulot is Professor of Medicine, Pharmacology at Paris University, Paris, France. He is a medical cardiologist with a PhD degree in clinical and experimental pharmacology at the René Descartes Paris 5 University. From 2010 to 2014, he served as an Associate Professor of Medicine, Cardiology at the Cardiovascular Research Center at Mount Sinai School of Medicine in New York, USA.
Since 2014, he is leading an INSERM-labelled research team investigating on novel molecular mechanisms that drive heart failure. The studies include animal models but also translational models based on human induced pluripotent stem cells & genome editing approaches. A main research focus is elucidation of mechanisms that drive cardiac hypertrophy and adverse fibrotic remodeling of the heart.
Ewa A. Jankowska, MD PhD, FESC FHFA, is the professor of cardiology and geriatrics, the Head of Laboratory of Applied Research on Cardiovascular System Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland, and Centre for Heart Diseases, Military Hospital, Wroclaw, Poland.
Her clinical and scientific interest relates to heart failure (HF) and the process of aging: 1) the role of peripheral pathomechanisms in the progression of HF, including cardiorespiratory reflex control and hormone derangements (catabolic/anabolic imbalance, androgen/estrogen imbalance); 2) co-morbidities in HF, including cardiorenal anaemia syndrome and iron deficiency; 3) risk stratification in HF, including a set of multiple biomarkers (neurohormones, iron status, steroid hormones, vital signs, including heart rate, congestion); 4) the role of skeletal muscles and exercise training in HF; 5) acute HF; 6) experimental model of tachycardia-induced cardiomyopathy in pigs; 7) male aging, andropause. She has been involved in several research projects and clinical trials in these areas, currently being the co-PI of the AFFIRM-AHF trial (intravenous ferric carboxymaltose in acute HF), the PI in 2 research grants (National Research Center, Poland) and the major investigator in 11 Polish grants and 5 European projects. She is the co-author of >400 scientific papers in peer-reviewed journals, IF >800, ISI Web of Science Citations >5000, Hirsch index 30.
She was awarded several times by Ministry of Health in Poland, and received the Scientific Award of the Polish Prime Minister for the habilitation dissertation (PhD theses) and scientific output as well as the Scientific Award of the Presidents of the Polish Society of Cardiology.
Area of expertise: Prof.Lixin Jiang’s primary focus and area of expertise is in the fields of large-scale clinical trial, healthcare quality assessment and improvement, large-scale population cohort and biobank, health policy, and global health.Being academically prolific, she has published more than 160 articles during the past five years.
Prof.Lixin Jiang, MD, PhD, is the Vice President of Fuwai Hospital, CAMS. She is a Fellow of ESC, AHA and ACC, the Co-Chair of WHO GCM/NCD Working Group on Health Education and Health Literacy for NCDs, and the Member of Management Committee of Global Alliance for Chronic Diseases (GACD). Serving as the Editor-in-Chief, The Lancet Chinese Edition, Prof. Jiang is a member of the International Advisory Board, Lancet.
In 2016, Prof. Jiang was honored with Women Transforming Leadership Program Award by European Society of Cardiology.
Area of expertise: e-Cardiology, Digital health, m-Health and e-Health, preventive cardiology and cardiac rehabilitation.
Area of expertise: His clinical and research interest is cardiovascular medicine with particular emphasis on heart failure, pharmacotherapy, and metabolism with body composition.
Dr. Mitja Lainscak is Professor at Faculty of Medicine, University of Ljubljana and does clinical practice & research at Division of Cardiology, General Hospital Murska Sobota, Slovenia.
Currently he holds an Executive Committee member position at the Heart Failure Association of the ESC, and is a Fellow of the HFA and of the ESC. In 2018, he was the Scientific Chairperson of the Heart Failure Association annual congress. Professor Lainscak has published more than 200 papers and contributed to several book chapters. He is Associate Editor at Journal of Cachexia, Sarcopenia, and Muscle and ESC Heart Failure.
Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program, Director of the Clinical & Translational Research Office at NHCS, Scientific Advisor to the Clinical Trials Coordinating Centre at SingHealth, and Affiliate Member of the SingHealth Duke-NUS Institute of Precision Medicine. She graduated from the Faculty of Medicine, National University of Singapore, completed advanced specialty training in Cardiology in Singapore, and pursued her Research Fellowship at the Cardiorenal Laboratory, Heart Failure Fellowship at the Division of Cardiovascular Diseases, and Advanced Cardiology and Master of Biomedical Sciences at Mayo Clinic, Rochester MN. She further received training in clinical and genetic epidemiology at the Framingham Heart Study in Boston, MA, graduated from the Stanford Executive Programme and obtained her PhD at University Medical Centre Groningen.
Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials. She started the first Heart Failure with Preserved Ejection Fraction Programme and Women’s Heart Health Clinic in Singapore, was awarded the NMRC Clinician Scientist Award (2010) and the L’Oreal Women In Science Award (2012) for her work in heart failure and women’s cardiovascular disease respectively, was named an InterAcademy Medical Panel Young Physician Leader at the World Health Summit in Berlin (2012), won the award for the Junior Chamber International (JCI) Ten Outstanding Young Persons of the World for 2014 –Singapore (2014), and is a current recipient of the NMRC Senior Investigator Clinician Scientist Award. She is the Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) – an A*STAR Biomedical Research Council-funded research platform; and principal investigator of an ongoing nation-wide heart failure study in Singapore (the Singapore Heart Failure Outcomes and Phenotypes [SHOP] study), a multinational Asian study of heart failure across 11 Asian countries (Asian Sudden Cardiac Death in Heart Failure [ASIAN-HF] study). She serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and European Journal of Heart Failure. Finally Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of the health programme “Body and Soul” by MediaCorp Singapore.
Ekaterini Lambrinou holds a PhD, a Master’s in Clinical Nursing and a BSc from the University of Athens. She has been a visiting lecturer at the Faculty of Nursing of the University of Athens and the University of Peloponnese. Her most professional clinical experience was in the intensive care unit at the 1st Cardiology Department of Athens Medical School, at the Hippocration Hospital in Greece, where she gained great experience on the care of people with cardiovascular diseases.
With a background in gerontology (PhD), and intensive cardiology care, her research interests include: nursing in relation to the care of older people and nurses’ role in the strategies of prevention and management of patients with cardiovascular diseases. Heart failure management is her main interest since it is one of the most common health problems of older people. Most of her publications and citations are referred to the particular topic.
Ekaterini Lambrinou is the Chair of the Council of Cardiovascular Nurses and Allied Professions (CCNAP). She has also sat for four years on the Board of the European Heart Failure Association and of the European Society of Cardiology and served in several committees.
Ekaterini Lambrinou is an associate professor and the first elected academic staff at the Department of Nursing of the Cyprus University of Technology. She has been a member of the advisory committee for the development of the undergraduate programme of the Nursing Department and contributed to the transition programme of diploma to Bachelor degree in Nursing. She is also involved in the development of postgraduate programmes in advanced nursing in Cyprus and nurse practitioners and she is the Director of the MSc programme in Advanced Acute and Intensive Cardiology Care.
Paul Leeson is Professor of Cardiovascular Medicine at the University of Oxford and Director of the Oxford Cardiovascular Clinical Research Facility. He is also a Consultant Cardiologist at the John Radcliffe Hospital, where he provides expertise in cardiovascular imaging and hypertension. He heads the Preventive Cardiology Research Group, which develops imaging technologies, and undertakes clinical studies, to improve identification and prevention of cardiovascular disease.
Cecilia Linde MD, is Professor and consultant in Cardiology at the Heart and Vascular Theme at the Karolinska University Hospital in Stockholm, Sweden.
Her research currently focuses devices and epidemiology in heart failure. She was co-chairman in the MUSTIC study, principal investigator of the REVERSE study, which was to first to show a benefit of CRT in mild heart failure and the MIRACLE-EF study. She initiated the KaRen registry of HFpEF patients with Professor Daubert Rennes University. She is co-chairman of the Stockholm PREFERS studies with focus on epidemiology imaging and biomarkers in HFpEF and hypertension in the search of new drug targets.
Dr Linde is the author of >250 papers, reviews and editorials in a wide variety of fields including CRT, haemodynamic monitoring and HFpEF and she serves on the editorial board of several journals. She has been a board member of the European Heart Rhythm Association (EHRA) for which she was scientific programme Chair 2013-2015 and has served on many guidelines writing committees of EHRA and Heart Failure Association She is co-PI of the European CRT survey II covering 10.088 CRT implantations across 42 European countries. She was appointed Doctor Honoris causa at the University of Rennes in April 2015 and Honorary member of the Hungarian Cardiac Society in 2017. .
Cecilia Linde is a Board member of the ESC for the period of 2016-2018 and is member of the Scientific Committee of Heart Rhythm Society. She is treasurer of European Heart Rhythm association (EHRA).
Area of expertise: Circulatory support in cardiogenic shock and cardiac arrest.
Roberto Lorusso is Associate Professor at the Cardio-Thoracic Surgery Department of the Maastricht University Medical Centre. He has a PhD on alternative techniques for chronic cardiomyopathy, master degrees on Minimally Invasive Cardiac Surgery and in Health Care Management. Young Investigator Award by the European Association for Cardio-Thoracic Surgery. Previously, Director of School of the European Association for Cardio-Thoracic Surgery (EACTS) (2008-2012), Scientific Secretary of the Italian Society for Cardiac Surgery (2007-2008), President of the Euro-ELSO organization (ECMO)(2015-2017), and currently Editor-in-Chief of the MultiMedia Manual of Cardio-Thoracic Surgery (EACTS).
Area of expertise: I’m a interventional cardiologist, mainly dedicated to coronary intervention, with over 30 years of experience in this field, being the Interventional Cardiology Unit Director in a University Hospital. I’m also the Director of Cardiovascular Diseases in Catalonia, where I work with Health Authorities in providing equity and the best cardiovascular care to population, from prevention to rehabilitation. My life goal is to combine personal and professional development for the benefit of others.
I have been working as a cardiologist from 1987. I achieved MD PHd degree in 1992, while I was expecting my second child. I have been involved in different institutional positions: President of Spanish Working group on Intravascular imaging, president of Spanish Working group on Percutaneous Cardiac Interventions, member of Euro-PCR program committee, and I have been deeply involved in ESC, being co-chair and chair of EAPCI Women Committee, and nowadays the chair of Patient Initiatives Committee and Advocacy EAPCI Pillar.
Lucia Mazzolai is a clinical vascular specialist and a full Professor, head of the Angiology division and director of the Heart and Vessel Department of the University Hospital of Lausanne, in Switzerland. She completed her medicine studies in Italy, Perugia, a PhD program at the Scripps Research Institute in San Diego, USA, and a post doctoral fellowship at the University of Lausanne in Switzerland. Currently secretary of the ESC WG on Aorta and peripheral circulation. Area of expertise: peripheral artery disease and venous thromboembolism. She is author of over 150 publications.
Julinda Mehilli, M.D., is Professor at the Ludwig-Maximilians University in Munich and Director, Department of Cardiology, Zentralklinikum Bad Berka, Germany. Dr. Mehilli is a practicing interventional cardiologist with broad expertise in both coronary and structural percutaneous intervention. She has longstanding research interest in cardiovascular medicine, particularly in the field of drug-eluting stent design, peri-interventional antithrombotic therapy, interventional treatment of aortic valvular disease and the impact of gender on cardiovascular outcomes. She has served as principal investigator of several investigators initiated trials the most recent ones REBOOT, TROPICAL-ACS, ISAR-REACT 4, ISAR-TRIPLE, ISAR-LEFT MAIN 1&2, ISAR-CABG, BRAVE 4. She has authored over 300 publications in cardiovascular research across the spectrum of prestigious internal medicine and cardiology journals.
Area of expertise: coronaries, valve clinical research
Dr Morice is an interventional cardiologist with more than 30 years of experience as Head of the highest-volume PCI centers in the Greater Paris Area (CCN, ICPS). A fellow of the ESC and the ACC, Honorary Professor of the Universidad Del Salvador in Buenos Aires and a Senior Consulting Adviser to EuroPCR, she is a guest lecturer and chairperson at all major international Cardiology scientific sessions. Dr Morice has been involved in multiple landmark research trials such as RAVEL and SYNTAX as a Primary Investigator and has published more than 300 peer-reviewed articles. She is the President and Medical Director of the European Center for Cardiovascular Research (CERC). In 2013, Dr Morice was designated Best Interventional Cardiologist in France and in 2014 she received the CHIEN award during ASIA PCR and the Geoffrey O. Hartzler Master Operator Award at TCT 2014 for her career achievements.
Area of expertise: Personal scientific expertise: vascular cell biology. General expertise: broad knowledge of EU cardiovascular research and its leaders.
Current Chair, ESC Basic Cardiovascular Science Council. Associate Medical Director (Research) in the British Heart Foundation, the major funder of academic cardiovascular research in the UK, supporting over 80 career development fellows and over 30 professors. Emeritus Professor of Vascular Biology, King’s College London.
Area of expertise: Professor Piepoli’s research interests are in autonomic nervous system, Cardiac Prevention and Rehabilitation, Exercise Physiology and Heart Failure.
He currently heads the Heart Failure and Cardiomiopathy Unit of the Guglielmo da Saliceto Polichirurgico Hospital in Piacenza. He is Teaching Professor in the Schools of Cardiology of the University of Parma and at the Fondazione Monasterio, Pisa.
Avital Porter MD, graduate of the Ben- Gurion Medical School in Israel. Board Certified in Internal medicine and Cardiology (Israel).
In 2013 a rotation at Cedars Sinai Women Cardiac Health Center, with Dr. Bairey Merz, director of the "Barbara Streisand" Women heart Center.
Current position: Head of the cardiology unit (step down ICCU) – since 2005, and The Women's Health Center- since 2013 , Rabin Medical Center , Petah Tiqva Israel
For the last couple of years I am involved in promoting women's cardiovascular health, as well as women's leadership in cardiology
As the continuum of clinical activities on December 10, 2014 Rabin Medical Center women heart center launched the first in Israel national Meeting on women's cardiac health: Cardio-femme. In July the fifth national Cardiofemme meeting is taking place, as a part of women's cardiac health promotion.
Area of expertise: Dr Remme’s research encompasses basic and translational studies on cardiac sodium channel (dys)function and inherited sodium channelopathies (including SCN5A mutations) associated with cardiac arrhythmias and sudden cardiac death (SCD), incorporating clinical and genetic data with functional and mechanistic studies in transgenic models and human induced pluripotent stem cell-derived (iPSC) cardiomyocytes. Her work additionally focuses on identifying and validating novel genes and pathways modulating cardiac electrophysiology, arrhythmias, and SCD.
Carol Ann Remme (MD PhD) studied Medicine at the University of Utrecht, The Netherlands. After completing her PhD at the University of Amsterdam, The Netherlands, she decided to focus her career on research. She is currently Principal Investigator and Associate Professor of Basic and Translational Cardiac Electrophysiology at the Department of Clinical and Experimental Cardiology of the Academic Medical Center in Amsterdam. In addition, she serves on the Editorial Board of a number of international journals, and is currently Vice-Chair of the ESC European Working Group on Cardiac Cellular Electrophysiology.
Areas of expertise: Cardiovascular Pharmacology and Heart Failure
He has authored over 400 peer-reviewed articles, 5 books and 28 book chapters.
He currently serves as an expert in the area of Cardiovascular Medicine for the European Assessment Office of the Italian Drug Agency (AIFA), he is core member of the Cardiovascular Working Party of the European Medicines Agency.
He is board member of the Heart Failure Association (HFA) and Nucleus member of the Working Group on Cardiovascular Pharmacotherapy of the ESC.
Area of expertise: Professor Serruys established the methodology of QCA and tried to elucidate the phenomenon of restenosis post angioplasty. After unsuccessful pharmacological trials to control restenosis phenomenon, his scientific focus was shifted to mechanical device engineering such as stenting. He conducted the first randomized trial with stenting called the BENESTENT trial. Then he introduced the use of drug-eluting stents for the first time in the world in 1999 with Eduardo Sousa in Brazil. In 2006 he introduced the use of a bioresorbable scaffolds as well as a self-expandable trans-catheter aortic valve such as CoreValve with Eberhard Grube. In the next decade, he will dedicate his scientific interest to investigate non-invasive and automatic diagnosis of coronary artery disease using MSCT and artificial intelligence, video-densitometric assessment of paravalvular regurgitation after TAVI and invasive assessment of shear stress in coronary artery disease.
Patrick W. Serruys (1947, H-index: 170) has been a senior interventional cardiologist since 1977, Chief of Interventional Research since 1988, Head of Interventional Cardiology at the Thoraxcenter from 1997-2012, Emeritus Professor of Medicine since April 2014 at Erasmus MC. Prof. Serruys was the first chair of interventional cardiology created by the Royal Netherlands Academy of Arts and Sciences. Currently he is professor of Cardiology in the Cardiovascular Science Division of the National Heart and Lung Institute (NHLI) of Imperial College in London (UK).
Area of expertise: My research expertise is related to arterial function and structure with special interests on the predictive role of vascular biomarkers for cardiovascular events and how these biomarkers can be incorporated into clinical practice. I have studied the effect of lifestyle (smoking, diet, exercise, psychological factors), pharmacological agents and inflammation on arterial function, and the relation between cardiovascular disease and sexual dysfunction. My research interests extend to pathophysiology of hypertension and dyslipidemia.
I am an Associate Professor of Cardiology at the 1st Department of Cardiology of Athens Medical School with clinical interests in hypertension, dyslipidemia and interventional cardiology. I have published more than 250 peer-review articles that have been cited in over 35,000 referenced publications. My H-index is 64. I am member of the Task Force of 2016 European Society of Cardiology/European Atherosclerosis Society Guidelines on the Management of Dyslipidemias and of the 2017 European Society of Cardiology Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. I served as Chairman of the ESC Working Group of “Peripheral Circulation” and the ARTERY Society. Together with Wilmer Nichols and Michael O’Rourke I authored the 6th Edition of “McDonald’s Blood Flow in Arteries”. I have lectured extensively in international conferences.
Area of expertise: Vascular Biology and Interventional Cardiology
Dr. Waltenberger received his medical degree from the Ruprecht-Karls-University in Heidelberg in 1988. Following internship in Heidelberg and postdoctoral training in Uppsala, Sweden, he completed his residency training at the University of Ulm, Germany, where he joined the medical faculty later on. From 2003 through 2010, he served as Professor of Interventional Cardiology at Maastricht University Medical Center, the Netherlands. The past 7 years, he served as Professor of Internal Medicine, Cardiology and Vascular Medicine at the Westfalische-Wilhems-University of Muenster, Germany. He had been sitting in the Board of the ESC as COuncillor from 2008 to 2010, and is the incoming Chair of the Concil on Basic Cardiovascular Sciences of the ESC.
Area of expertise: Research interests/expertise include coronary interventions and physiology, coronary microcirculation, arterial hypertension and arterial stiffness.
Following cardiology training and PhD, pursued a clinical/research fellowship in interventional cardiology with focus on coronary physiology (OLV-clinic, Aalst, Belgium). These were supported by grants by the EAPCI and the Hellenic Cardiological Society and resulted in publications in major peer-reviewed journals. Nucleus member of the ESC working group on aorta and peripheral vascular diseases. Currently working as attending interventional cardiologist at CHU Saint-Pierre University Hospital, Brussels, Belgium.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved